Clinical Trials
13
Active:1
Completed:2
Trial Phases
4 Phases
Phase 1:8
Phase 2:3
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (61.5%)Phase 2
3 (23.1%)Not Applicable
1 (7.7%)Phase 3
1 (7.7%)A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Phase 3
Not yet recruiting
- Conditions
- Recurrent and Refractory Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Selinexor TabletsDrug: Purinostat Mesylate for Injection
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 390
- Registration Number
- NCT07011056
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- Drug: Purinostat Mesylate 4 mg/m2Drug: Purinostat Mesylate 6 mg/m2Drug: Purinostat Mesylate 8.4 mg/m2
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT06484829
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Cutaneous T-cell Lymphoma (CTCL)Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Interventions
- Drug: 11.2 mg/m2 Purinostat MesylateDrug: 15 mg/m2 Purinostat Mesylate
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06485219
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳West China Hospital Sichuan University, Chengdu, Sichuan, China
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
Phase 2
Recruiting
- Conditions
- MF,PMF,PPV-MF,PET-MF
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT06457425
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
ZL-82 Double-blind Clinical Trial
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06432738
- Locations
- 🇨🇳
Peking University Medical Shandong Hospital of Traditional Chinese Medicine, Zibo, Shandong, China
- Prev
- 1
- 2
- 3
- Next
News
No news found